Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF

BACKGROUND: The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy or develop resistance during treatment, the search for alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebert, Karolin, Haffner, Ivonne, Zwingenberger, Gwen, Keller, Simone, Raimúndez, Elba, Geffers, Robert, Wirtz, Ralph, Barbaria, Elena, Hollerieth, Vanessa, Arnold, Rouven, Walch, Axel, Hasenauer, Jan, Maier, Dieter, Lordick, Florian, Luber, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908634/
https://www.ncbi.nlm.nih.gov/pubmed/35264144
http://dx.doi.org/10.1186/s12885-022-09335-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908634/
https://www.ncbi.nlm.nih.gov/pubmed/35264144
http://dx.doi.org/10.1186/s12885-022-09335-4

Ejemplares similares